Back to Browse Journals » Open Access Journal of Clinical Trials » Volume 2

HeartSmart® for routine optimization of blood flow and facilitation of early goal-directed therapy

Authors Kenneth Warring-Davies, Martin Bland

Published Date August 2010 Volume 2010:2 Pages 115—123


Published 5 August 2010

Kenneth Warring-Davies1, Martin Bland2
1The Intensive Care Unit, Bradford Royal Infirmary, Bradford, West Yorkshire, UK; 2Department of Health Sciences, University of York, York, North Yorkshire, UK

Abstract: The empirical physiological formulae of the new continuous cardiac dynamic ­monitoring HeartSmart® technology, which involves the use of a new inverse square rule of the heart, were investigated with pulmonary artery catheter (PAC) thermodilution in the ­estimation of CI in diverse patients. Clinical trial data collected from 268 adult surgery or intensive care patients requiring PAC placement were obtained from 7 NHS Trust hospitals, providing 2720 paired sets of CI estimations for comparison between HeartSmart® and PAC thermodilution. For 95% of pairs of measurements, HeartSmart® values were between 57% and 164% of PAC measurements; additionally, the larger limit of agreement between HeartSmart® and PAC thermodilution (1.26 L min-1•m-2) suggests that HeartSmart® agrees with PAC thermodilution as closely as PAC thermodilution agrees with itself. HeartSmart® can also estimate CI in the extreme circumstances of shock/sepsis, as indicated by PAC thermodilution CI values that were hypo- or hyperdynamic based on systemic inflammatory response syndrome criteria. In CI measurements for hypo- or hyperdynamic values that were matched between HeartSmart® and PAC thermodilution, the difference in total volumes and average CI measurements between the two methods was less than 5%. For unmatched hypo- or hyperdynamic values, the difference between total volumes and average CI measurements was less than 33% – an acceptable percentage of difference or error even for normal values of CI. HeartSmart® tracked PAC thermodilution CI hypodynamic values 98.2% of the time and hyperdynamic values 97.6% of the time. These findings show that CI estimations provided by the HeartSmart® empirical physiological formulae are comparable to those obtained using PAC thermodilution. HeartSmart® removes many of the technical barriers that prevent the routine adoption and practice of early goal-directed therapy, and represents a simple, reliable method of estimating CI and other hemodynamic variables at the bedside or in departments other than the Intensive Care Unit.

Keywords: cardiac index, early goal-directed therapy, HeartSmart®, cardiodynamics, blood flow

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Plain packaging of cigarettes: do we have sufficient evidence?

Smith CN, Kraemer JD, Johnson AC, Mays D

Risk Management and Healthcare Policy 2015, 8:21-30

Published Date: 2 April 2015

Lessons learnt from implementing an empirically informed recruitment approach for FEM-PrEP, a large HIV prevention clinical trial

Parker C, Corneli A, Agot K, Odhiambo J, Asewe J, Ahmed K, Skhosana J, Ratlhagana M, Lanham M, Wong C, Deese J, Manongi R, Van Damme L

Open Access Journal of Clinical Trials 2015, 7:1-9

Published Date: 19 December 2014

Pediatric clinical trials: a US perspective

Oelstrom MJ, Hoover-Regan ML

Open Access Journal of Clinical Trials 2014, 6:127-138

Published Date: 26 November 2014

Publication bias: what is it? How do we measure it? How do we avoid it?

Song F, Hooper L, Loke YK

Open Access Journal of Clinical Trials 2013, 5:71-81

Published Date: 4 July 2013

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia

Keller-von Amsberg G, Koschmieder S

OncoTargets and Therapy 2013, 6:99-106

Published Date: 4 March 2013

Motivators, enablers, and barriers to building allied health research capacity

Pager S, Holden L, Golenko X

Journal of Multidisciplinary Healthcare 2012, 5:53-59

Published Date: 20 February 2012

Is radical prostatectomy the best option for localized prostate cancer? Current opinion and research

Mike D Shelley, Malcolm D Mason

Open Access Surgery 2010, 3:47-58

Published Date: 21 July 2010